ArticleMicrobial cell factories2026
Statistical optimization of Chlorella vulgaris polysaccharides-mediated synthesis of platinum nanoparticles with dual functions: anticancer and anticoagulant activities.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe biomedical application of platinum nanoparticles (PtNPs) has gained increasing attention in recent years; however, conventional chemical synthesis often depends on harsh conditions and toxic reagents, which restrict their medical use due to concerns of cytotoxicity and environmental hazards. As a result, the development of eco-friendly and biocompatible methods has become a major focus in nanobiotechnology. This study introduces a green method using intracellular polysaccharides from Chlorella vulgaris strain ESA251 as reducing and stabilizing agents to create biocompatible CV-PtNPs, evaluating their dual anticancer and anticoagulant activities.
resultsPolysaccharides were extracted from Chlorella vulgaris strain ESA251 and characterized by GC-MS, revealing a heteropolysaccharide composition rich in glucose, mannose/galactose, rhamnose, and uronic acid. Platinum nanoparticles were synthesized under optimized conditions (20 mL polysaccharide extract, 40 mL 0.5 mM Hexachloroplatinic acid hexahydrate (H2PtCl6.6H2O), 97 °C, pH 12, 1 h, identified by plackett-Burman design (PBD). UV-Vis, Fourier Transform Infrared spectroscopy (FTIR), Transmission Electron Microscopy (TEM), and Scanning Electron Microscopy (SEM) confirmed the formation of quasi-spherical, well-dispersed nanoparticles predominantly within the nanoscale range (~ 5–20 nm) stabilized by hydroxyl, carbonyl, and ether groups. In vitro assays showed dose-dependent cytotoxicity against Human Breast Adenocarcinoma (MCF-7) and Human Hepatocellular Carcinoma (HepG-2) cancer cells, with IC50 values of 20.9 µg/mL and 74.1 µg/mL, respectively. These values suggest promising anticancer activity compared with previously reported chemically synthesized PtNPs. Anticoagulant studies demonstrated inhibition of visible clot formation under the tested in vitro conditions, highlighting them as potential anticoagulant candidates requiring further validation. This dual functionality may provide a basis for future exploration of combined anticancer and anticoagulant strategies, potentially relevant to limiting circulating tumor cell survival.
conclusionThese findings demonstrate that Chlorella vulgaris functions as an efficient microbial platform for the statistically optimized and sustainable biosynthesis of biologically active platinum nanoparticles, supporting their further evaluation in anticancer and anticoagulant research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.